Breast Cancer

CHEK2, P53, PTEN for breast cancer genetic testing – pro

Despite a negative (normal) genetic test for mutations in the BRCA1 and BRCA2 genes, about 12 percent of breast cancer patients from high-risk families carried previously undetected cancer-associated mutations. Risks for young women with inherited BRCA1 or BRCA2 mutations are particularly increased. Among white women in the U.S., 5 percent to 10 percent of breast cancer cases are due to inherited mutations in BRCA1 and BRCA2. Inherited mutations

Read more
Veristrat: Current Status – pro

VeriStrat® is a blood-based predictive and prognostic proteomic test for patients with advanced non-small cell lung cancer who test negative for EGFR mutations (EGFR wild-type) or whose EGFR mutation status is unknown. Veristrat was presented in April the 3rd European Lung Cancer Conference in Geneva, Switzerland. The VeriStrat test was validated through a retrospective analysis was performed on serum samples from advanced non-squamous non-small

Read more